Half-Year 2022 Financial and Clinical Trials Update slide image

Half-Year 2022 Financial and Clinical Trials Update

gRED oncology development programs Roche Molecule Indication Phase # of patients Status CT Identifier Oncology KRAS G12C (RG6330) cevostamab (anti-FcRH5 x CD3; RG6160) runimotamab (HER2 x CD3, RG6194) NME (RG6286) Metastatic solid tumors with KRAS G12C mutation 270 FPI Q3 2020 NCT04449874 FPI Q3 2017 R/R multiple myeloma 300 NCT03275103 Data presented at ASH 2020, ASH 2021 Metastatic HER2-expressing cancers 440 FPI Q2 2018 NCT03448042 Locally advanced or metastatic 67 FPI Q3 2020 NCT04468607 colorectal cancer Solid tumors 1/11 250 FPI Q1 2020 IL15/IL15Ra-Fc (RG6323)1 R/R multiple myeloma | 60 FPI Q2 2022 NCT04250155 NCT05243342 FPI Q4 2017 Solid tumors la/llb 271 autogene cevumeran (Individualized Neoantigen-Specific Therapy (iNeST); RG6180)² 1L advanced melanoma || = 132 FPI Q1 2019 Data presented at AACR 2020 Recruitment completed Q1 2022 NCT03289962 NCT03815058 (IMcode001) NCT04252339 SHP2i (RG6344) Solid tumors la ~50 FPI Q1 2020 belvarafenib (RG6185)³ nRASmt CPI-experienced melanoma lb 83 FPI Q2 2021 NCT04835805 ISRCTN92655 NME (RG6392) Oncology 60 FPI Q4 2021 801 Partner: 1Xencor, 2BioNTech, ³Hanmi 157
View entire presentation